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ABSTRACT 
OBJECTIVES:  To present the histopathological pattern of urinary bladder neoplasms using the 
WHO/ISUP classification system and relate it to the outcome. 
METHODS: This study was conducted in the period from January 2004 through December 2005 at 
three centres in Khartoum, Sudan. One hundred and six patients with urinary bladder neoplasms 
were included in the study.  
RESULTS: The commonest affected age group was 60-80 years with male to female ratio 4.6:1. 
Urothelial neoplasms were found in 72 (67.9%), Squamous cell carcinoma (SCC) in 26 (24.5%), 
urothelial neoplasms with Squamous differentiation in 3 (2.8%), and other types in 5 (4.7%) of the 
patients.  There were 43.4% of the urothelial neoplasms graded as papillary carcinoma of high 
grade, 52.6% papillary carcinoma of low grade, 1.3% papillary neoplasm of low malignant 
potential, 1.3% papilloma, and 1.3% was graded as flat neoplasm.  Of the SCCs, twelve (42.9%) 
were poorly differentiated SCCs, nine (32.1%) moderately differentiated, and seven (25%) cases 
were well differentiated SCCs.  Follow-up information was available in 32 patients.  At last follow-
up, fifteen (46.9%) patients were dead of the disease, twelve (35.5%) were alive with no evidence 
of disease, four (12.5%) were alive with disease, and one (3.1%) was alive and terminally ill.  
CONCLUSION: Histological grade (P: 0.006), and muscle invasion (P: 0.002) were significantly 
associated with survival. A subset of the cases could not be assessed for muscle invasion due to 
inadequate sampling; we thus recommend proper trans-urethral bladder biopsy (TUBP) sampling. 
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lthough there are improvements in 
detection and management of urinary 
bladder neoplasms (UBN), the death 
toll remains high. 
The histopathological pattern and outcome of 
UBN have not been identified to date in 
Sudan. Such information would facilitate 
preoperative risk stratification and case-mix-
adjusted outcome comparison, and lead to the  
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 development of processes of care directed at 
improving outcomes and ultimately the 
quality of care for bladder carcinoma patients. 
A number of classification systems have been 
used to grade papillary neoplasms of the 
urinary bladder1,2. Grading of the UBN 
depends on the histology of the urinary 
bladder which has a similar composition to 
the ureters and renal pelvis, with the 
innermost lining being transitional epithelium 
(urothelium) and, extending outward, as 
lamina propria, muscularis propria, and 
adventitia or serosa3.  The muscularis propria 
is divided into inner and outer longitudinal 
layers and a central circular layer; these are 
best individualized in the bladder neck 
region4.     These anatomic landmarks are 
important for evaluating the depth of invasion 
of a bladder neoplasm.  
A
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The most widely used grading system is the 
World Health Organization (WHO) 
classification, introduced in 19735.  In an 
attempt to achieve uniformity in reporting and 
to improve the terminology, in 1998 the 
World Health Organization/International 
Society of Urologic Pathologists 
(WHO/ISUP) has introduced a consensus 
classification for grading of urothelial 
neoplasm of the urinary bladder 6,7. This 
system was also adopted in the most recent 
WHO system for classifying bladder tumor, 
which will hopefully lead to an even greater 
consensus8.   It recognizes a rare benign 
papilloma, a group of papillary urothelial 
neoplasms of low malignant potential, and 
two grades of carcinoma (low and high 
grade). Its main features are the division of 
the neoplastic lesions into flat and papillary 
and the separate evaluation of the papillary 
neoplasms for grade (based on architecture 
and cytology) and invasiveness (divided into 
lamina propria and muscularis propria 
levels)2.  
        The presently recommended 
nomenclature by the WHO is similar to the 
WHO/ISUP classification of 1998, but the 
diagnostic criteria are further defined for 
practice. The terms non-invasive have been 
added to low and high grade papillary 
carcinoma to emphasize biologic differences 
between these tumors and infiltrating 
urothelial cancer8. 
Methods 
      This is a descriptive retrospective 
study conducted in three medical centres: 
Soba University Hospital, Ibn Sina Hospital 
and the National Health Laboratory at 
Khartoum, Sudan. Soba University Hospital is 
a teaching university hospital. Ibn Sina 
Hospital is a specialized hospital for renal and 
gastrointestinal diseases.  The National Health 
Laboratory (NHL) stands as a national 
reference laboratory and receives samples 
from different parts of Sudan. 
Patients diagnosed to have urinary bladder 
neoplasms in the period from January 2004 
through December 2005, were studied. 164 
patients were reviewed, of which 106 were 
included in the study.   
Exclusion criteria:  
Patients who were not diagnosed 
histopathologicaly at the three centres and 
those with no adequate information were 
excluded (n= 58).    
Data were collected using patient's records, 
direct interviews and a pre-designed 
questionnaire. The questionnaire covers all 
the personal information, the presenting 
symptom, its duration and the biopsy 
technique.  Cystoscopy findings, tumor size 
as well as type of surgery were also reviewed. 
The formalin-fixed, paraffin-embedded 
histopathology slides were reviewed and the 
urothelial tumors were re-graded using the 
2004 (WHO/ISUP) grading system by a 
single experienced pathologist.   
Follow-up information was obtained from 
reviewing the pathology and clinical files and 
from contacting the attending physician or the 
patient himself or his family. Survival time is 
defined as the time from the diagnostic 
surgical procedure to the date of the most 
recent method of follow-up. The relationships 
between overall survival and tumor grade as 
well as overall survival and muscle invasion 
were investigated using the log-rank test9 for 
categorical variables and a score test based on 
the Cox proportional hazards model10 for 
continuous variables. 
Data were fed to Statistical Package of Social 
Sciences (SPSS), version 10. T-test (unpaired) 
was used for the difference of the means. 
Person's Correlation Coefficient was used and 
P < 0.05 was considered as statistically 
significant.     
Results  
  From January 2004 through 
December 2005, 106 patients were included 
in this study. 87(82.1%) patients were men.  
The male to female ratio   for TCC was 6.2:1 
but for SCC was 2.3:1. Their mean (±SD) age 
was 59.49 (±13.7) range (18-90) years. When 
the pathology was fractionated; the mean age 
for TCC was 60.92 and for SCC was 55.47. 
The peak frequency for all cases was at the 
age of 60-80 years.  
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The presenting symptom of UBN was 
gross heamaturia in 75 (84.3%), painful 
micturition in 35 (39.3%), urgency in 14 
(15.7%), palpable pelvic mass in 03 (03.4%), 
microscopic heamaturia in 03 (03.4%), and 
others in 41 (46.1%) of the studied patients. 
Other symptoms include suprapubic pain, 
urine retention, and weight loss.  The duration 
of symptoms varied from one week to 6 years. 
Among the total, 52.9% of the patients had 
symptoms <6 months duration, while 47.1% 
had symptoms of >6 months. In 80/106 
studied patients, the location of UBN in the 
cystoscopy examination was as follows: 
lateral walls, 36 (45%); anterior wall, five 
(6.3%); posterior wall, four (5%); dome, three 
(3.8%); neck, 2 (2.5%); ureteric orifices, 
2(2.5%); and multiple sites, 28 (35%). 39 out 
of 76 (51.3%) TCC cases were papillary, 19 
(25%) were solid, and 18 (23.7%) showed 
both papillary and solid configuration. 
  Forty eight out of eighty two (58.5%) 
patients showed tumor size of >6cm at 
presentation, thirteen (15.9%) were 3-6cm, 
and 21 (25.6%) were of <3cm at presentation.    
Eighty two (77.4%) of the specimens were 
trans-urethral bladder biopsies (TUBPs), 18 
(17%) were samples of trans-urethral 
resection of bladder tumors (TURBTs), four 
(3.8%) cystectomies, one (0.9%) was true-cut 
needle biopsy, and one (0.9%) specimen was 
obtained during laprotomy.   
Histopathologically, TCC with its different 
grades was seen in 72 (67.9%), SCCs in 26 
(24.5%), TCC with sqamous differentiation in 
three (2.8%) and others in five (4.7%) 
patients. The others include adenocarcinoma 
(2 patients), liposarcoma, leiomyosarcoma, 
and malignant fibrous histocytoma. There 
were 43.4% of TCC patients graded as 
papillary carcinoma of high grade (Figure 1), 
52.6% papillary carcinoma of low grade, 
1.3% papillary neoplasm of low malignant 
potential, one papilloma, and another was 
graded as a flat neoplasm at presentation. 
28/76(36.8%) of TCCs showed histologically 
signs of muscle invasion (infiltrative) at 
diagnosis and 21 (27.6%) with no muscle  
 
invasion, whereas 27 (35.5%) contain no 




Figure (1): Infilterative urothelial carcinoma, 
high grade. The architecture is disordered 
and there is nuclear pleomorphism, 
hyperchromasia and abnormal mitosis 
(arrowed). (H&E. X40). 
 
In the current study, 12 (42.9%) of the SCCs 
were poorly differentiated (Figure 2), nine 
(32.1%) moderately differentiated, and seven 
(25%) were well differentiated SCCs.  At last 
follow-up, 15 patients (46.9%) were dead of 
disease, 12 (35.5%) were alive with no 
evidence of disease, four (12.5%) were alive 
despite not being disease free, and one (3.1%) 
was alive and terminally ill. 
 
 
Figure (2):  Squamous cell carcinoma poorly 
differentiated. Large cells with pleomorphic 
nuclei, prominent nucleoli and mitosis 
(arrowed) (H&E. X40). 
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Figure 3 shows the relationship between 
muscle invasion and outcome of UBN in the 
studied patients.  Figure 4 shows the 
relationship between grades and outcome of 
UBN among the studied patients.
 
Figure (3):  Relationship between muscle invasion and outcome of UBN in the studied patients 
(P=0.002). 
 
Figure (4): Relationship between histological grades and outcome of UBN among the studied 
patients (P=0.006).  
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       Urinary bladder neoplasms are a 
heterogeneous group of tumors with different 
subtypes and behavioural patterns, there for, 
the epidemiological and clinicopathological 
comparison is relatively difficult.   
        The demographic characteristics of the 
patients in the current study were relatively 
similar to a number of previous studies, which 
describe a peak incidence in the seventh 
decade and predominance in men with a 
male-to-female ratio of 4:1 to 4.4:111,12.    
Clinically, the commonest presenting 
symptom was haematuria occurring in 87.7% 
of the patients. This was described as gross 
and painless hematuria in   84.3% of cases.  
To complicate matters it can be the only 
clinical presentation of urinary 
schistosomiasis, which is relatively common 
in sub-Saharan Africa. Due to lack of health 
awareness, in the under-developed nations, 
patients who develop bladder neoplasm in 
conjunction with schistosomiasis present with 
advanced disease. This in part explains the 
large number of patients presenting with other 
symptoms (46.1%) including suprapupic 
mass, obstructive uropathy and weight loss on 
the first visit.  
These results were similar to those of 
Sharfi et al who report that 82% of patients 
present with total painless haematuria13. 
There is an increased inter-individual 
variation in the duration of symptoms. In this 
study, it varies from one week to six years. 
Cystoscopically, the lateral walls were 
found to be the commonest site of occurrence 
of UBN (45%). This is nearly similar to what 
was reported in UK where the lateral walls 
were affected in 37% of patients I4. It differs 
from Sharfi’s study where the bladder bases 
were found to be the commonest site of 
occurrence of cancer (28%)13. It also differs 
from what was reported from Egypt where the 
base was affected in 44.6% of cases15.  
       Although 58.5% of the studied patients 
presented with large tumour size (>6 cm), 
tumor size did not show a significant effect on 
the outcome (P=0.761).  
   
 
     Since cystoscopy and biopsy are the main 
diagnostic measures, most of the specimens in  
 
this study were transurethral bladder biopsies 
(77.4%). 
 A common feature in this study to 
non-bilharzial bladder neoplasms is that 
histologically many were TCC (67.9%), while 
SCC accounted for 24.5%. This is relatively 
high when compared to a frequency of less 
than 5% in UK and USA8, and a relatively 
low   when compared to the figures reported 
from Egypt and Iraq where SCC forms the 
bulk of cases (66.7% and 65%), and TCC 
forms only 23.4% and 28% respectively15, 16. 
This may suggest that schistosomiasis is not 
the main predisposing factor to urinary 
bladder neoplasms among Sudanese patients. 
Thorough search for the etiological factors is 
bending. 
         Surprisingly, in the USA - a non-
bilharzia affected country- there are racial 
differences in histological findings, with 
Caucasians having 95% urothelial and 1.3% 
SCC, while the proportions in African 
Americans are 87.8% SCC and 3.2% 
urothelial neoplasms8. In South Africa, there 
are marked differences in histology between 
African Americans (36% SCC, 41% 
urothelial) and Caucasians (2% SCC, 94% 
urothelial)8. The association between race and 
the prevalence of SCC remains to be 
answered. 
Different variants of TCC were 
identified in this study including the nested 
variant, clear variant as well as a rare low 
grade TCC with lymphoplasmacytic infiltrate 
in the fibrovascular core, which is an unusual 
finding.  
         In this study, the findings of TCC 
configuration are contrary to those of Sharfi et 
al where 58% of tumors were solid, and 33% 
were papillary. Our findings differ with 
reports from Egypt where solid fungating 
tumors constitute 68.5% and Iraq (52%) of all 
bladder neoplasms15,16. It should be noted that 
the solid tumors form only 18.9% of non-
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bilharzial bladder cancer, 81.1% of which are 
papillary17.  
Recent advances in the morphological, 
molecular, and quantitative evaluation of non-
invasive, intraepithelial neoplasms of the 
urothelium have contributed to the refinement 
of the current classification and grading 
schemes. However, some controversies on the 
precise criteria and terminology exist, 
especially those concerning papillary 
lesions18.  
In this study, only 32 patients (33.3%) 
were followed. Of these, 46.9% died. The 
commonest cause of death in this study was 
renal failure due to involvement of the ureters 
rather than wide-spread metastasis. 
Despite the short duration of this 
study, follow up was difficult. This is due to a 
number of factors experienced in third world 
countries, the most important of which is that 
the majority of patients are based in rural 
underdeveloped regions.  Secondly, the 
impoverished rural hospitals are under 
equipped with cystoscopy armamentarium 
and no specialist urological surgeons. The 
poor educational health and awareness 
background of many patients made follow up 
difficult. Follow-up cystoscopy is usually 
missed despite patients are not pathology free. 
The recurrence rate within five years 
after partial resection was reported as high as 
78%19. However, in this series only 12.5% of 
the surgically resected lesions showed 
recurrences and this low percentage is mostly 
attributed to the difficulties in follow up of 
patients. 
In the current study, there is a 
statistically significant relationship between 
muscle invasion in TCC and the outcome of 
the disease (P=0.002). This is supported by 
Blaveri, et al who evaluated the associations 
between measures of genomic instability and 
bladder cancer clinical phenotype using array-
based comparative genomic hybridization and 
found that the fraction of genome altered was 
associated with worse outcome in muscle-
invasive tumors, independent of other 
clinicopathological parameters (P=0.002) 20. 
Tumor grade showed a significant 
association with the outcome (P=0.006) in 
this study. This is closely related to the 
findings of Messing E, et al. that, of the high-
grade or invasive cases, the proportion of late 
stage (T2 or higher) tumors were significantly 
lower in the screening-detected bladder 
cancers compared to unscreened ones 
(P=0.007). They pointed out to the 
importance of hematuria home screening 
which detects high-grade cancers before they 
become muscle invading. This significantly 
reduces bladder cancer mortality21. Better 
alternatives are presently available, and in the 
near future we will likely see urine tests for 
specific clinical conditions22. On the 
molecular level, there is no evidence for the 
benefit of routine screening for bladder 
cancer. However, prospective long-term 
studies are required to evaluate the benefits of 
bladder cancer screening; particularly in high 
risk groups23. It is time to detect 
cytogenetically high-grade cancers early, in a 
high risk population, in order to reduce 
bladder cancer mortality. 
 Conclusion: Urinary bladder neoplasms in 
this sample share some epidemiological 
features with other developing countries and 
others with developed countries. A high 
percentage of patients presented with locally 
advanced disease at the time of diagnosis. 
Pathologic grade and muscle invasion are the 
most valuable prognostic predictors of 
survival.  A subset of the cases could not be 
assessed for muscle invasion due to 
inadequate sampling. Thus improvements in 
the TUBP techniques would be of benefit. We 
stress the significance of public health 
education and awareness amongst patients 
and health care professionals. Bladder cancer 
screening awareness programs should be 
implemented to improve the outcome. 
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